Salvatore Mazzeo

Dr. Salvatore Mazzeo

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
VBValentina Bessi
Valentina Bessi
SMSalvatore Mazzeo
Salvatore Mazzeo
SPSonia Padiglioni
Sonia Padiglioni
CPCarolina Piccini
Carolina Piccini
BNBenedetta Nacmias
Benedetta Nacmias
LBLaura Bracco
Laura Bracco
The aim of this study was to evaluate the accuracy of neuropsychological assessment in predicting conversion from subjective cognitive decline (SCD) and mild cognitive impairment (MCI) to Alzheimer’s disease (AD) and the effect of personality traits

2 January 2019 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SMSalvatore Mazzeo
Salvatore Mazzeo
SPSonia Padiglioni
Sonia Padiglioni
SBSilvia Bagnoli
Silvia Bagnoli
LBLaura Bracco
Laura Bracco
BNBenedetta Nacmias
Benedetta Nacmias
VBValentina Bessi
Valentina Bessi

31 October 2023 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
CBChristopher R. S. Belder
Christopher R. S. Belder
CMCharles R. Marshall
Charles R. Marshall
JJJessica Jiang
Jessica Jiang
SMSalvatore Mazzeo
Salvatore Mazzeo
ACAnthipa Chokesuwattanaskul
Anthipa Chokesuwattanaskul
JWJason D. Warren
Jason D. Warren
Here, we review recent progress in the diagnosis and management of primary progressive aphasia—the language-led dementias. We pose six key unanswered questions that challenge current assumptions and highlight the unresolved difficulties that surround these diseases. How many syndromes of primary progressive aphasia are there—and is syndromic diagnosis even useful? Are these truly ‘language-led’ dementias? How can we diagnose (and track) primary progressive aphasia better? Can brain pathology be predicted in these diseases? What is their core pathophysiology? In addition, how can primary progressive aphasia best be treated? We propose that pathophysiological mechanisms linking proteinopathies to phenotypes may help resolve the clinical complexity of primary progressive aphasia, and may suggest novel diagnostic tools and markers and guide the deployment of effective therapies.

5 October 2023 in European Journal of Neurology
Verified
Journal Article
Open access
SMSalvatore Mazzeo
Salvatore Mazzeo
AIAssunta Ingannato
Assunta Ingannato
GGGiulia Giacomucci
Giulia Giacomucci
AMAlberto Manganelli
Alberto Manganelli
VMValentina Moschini
Valentina Moschini
VBValentina Bessi
Valentina Bessi
Background and purpose: We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).Methods: This longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD‐D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and 18F‐fluorodeoxyglucose‐PET) at baseline. The patients were rated according to the amyloid/tau/neurodegeneration (A/T/N) system and followed up for a mean time of 2.72 ± 0.95 years to detect progression from SCD to MCI and from MCI to AD. Forty‐eight patients (19 SCD, 29 MCI) also underwent plasma NfL measurements 2 years after baseline.Results: At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N−) with high accuracy (area under the curve [AUC] 0.82). We identified cut‐off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow‐up, nine SCD patients progressed to MCI (progressive SCD [p‐SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p‐MCI]). The previously identified cut‐off values provided good accuracy in identifying p‐SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p‐MCI (3.52 ± 4.06 pg/mL) compared to non‐progressive SCD (0.81 ± 1.25 pg/mL) and non‐progressive MCI (−0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954).Conclusion: Plasma NfL concentration and change over time may be a reliable, non‐invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.

27 September 2019 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
VBValentina Bessi
Valentina Bessi
SMSalvatore Mazzeo
Salvatore Mazzeo
SBSilvia Bagnoli
Silvia Bagnoli
SPSonia Padiglioni
Sonia Padiglioni
MCMarco Carraro
Marco Carraro
BNBenedetta Nacmias
Benedetta Nacmias

11 February 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SMSalvatore Mazzeo
Salvatore Mazzeo
SPSonia Padiglioni
Sonia Padiglioni
SBSilvia Bagnoli
Silvia Bagnoli
MCMarco Carraro
Marco Carraro
IPIrene Piaceri
Irene Piaceri
VBValentina Bessi
Valentina Bessi